Dr. Matt Killeen is the Chief Business Officer of Thryv Therapeutics.

Dr. Killeen brings nearly two decades of biopharmaceutical industry experience to Thryv, with deep expertise across portfolio strategy, business development, commercial strategy, and R&D leadership in cardiometabolic, rare/genetic, and CNS diseases. His career reflects a consistent focus on advancing first-in-class therapies and guiding strategic initiatives across multiple organizations.

Dr. Killeen previously founded the precision cardiology therapeutic area at BioMarin, where he served as Head of Cardiovascular R&D and built a portfolio of genetic therapies for inherited heart diseases. He then became the first Chief Scientific Officer of Renovacor (acquired by Rocket Pharmaceuticals), leading the development of gene therapies for genetic cardiomyopathies. Most recently, Dr. Killeen served as President of TikkunLev Therapeutics, where he launched the company and advanced a novel gene therapy for heart failure.

Earlier in his career, Dr. Killeen contributed to three CNS product launches at Biogen, led portfolio strategy efforts at BioMarin, and worked as a strategy consultant advising global biopharma companies in the US and Europe.

Dr. Killeen earned his Ph.D. in cardiac electrophysiology from the University of Cambridge and completed postdoctoral training as a research fellow at Harvard Medical School and Massachusetts General Hospital. He has authored more than 25 publications and is an elected Fellow of the Heart Rhythm Society, the American College of Cardiology, and the Royal Society of Biology.